Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Castle

Showing results (241-250 of 263) with videos related to

Pageof 27
Sort By:
The Australian and New Zealand Journal of Psychiatry|December 13, 2019
Meta-analysis of randomised controlled trials with <i>N</i>-acetylcysteine in the treatment of schizophreniaCaitlin Ob Yolland, Donal Hanratty, Erica Neill, et al.
BMC Psychiatry|September 16, 2016
N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptomsSusan L Rossell, Paul S Francis, Cherrie Galletly, et al.
JAMA Network Open|July 28, 2022
Association of Long-Acting Injectable Antipsychotics and Oral Antipsychotics With Disease Relapse, Health Care Use, and Adverse Events Among People With SchizophreniaYue Wei, Vincent K C Yan, Wei Kang, et al.
The Australian and New Zealand Journal of Psychiatry|May 15, 2020
Effectiveness of embedding a specialist preventive care clinician in a community mental health service in increasing preventive care provision: A randomised controlled trialCaitlin Mc Fehily, Kate M Bartlem, John H Wiggers, et al.
Trials|September 11, 2016
The Stroke and Carer Optimal Health Program (SCOHP) to enhance psychosocial health: study protocol for a randomized controlled trialCatherine Brasier, Chantal F Ski, David R Thompson, et al.
The Lancet Regional Health. Western Pacific|June 23, 2025
A decade of Benzodiazepine and Z-drug use in Hong Kong: a longitudinal studyKyung Jin Lee, Yue Wei, Shek-Ming Leung, et al.
Nutritional Neuroscience|May 31, 2018
Improvement of cognitive function in schizophrenia with <i>N</i>-acetylcysteine: A theoretical reviewCaitlin O B Yolland, Andrea Phillipou, David J Castle, et al.
Schizophrenia Bulletin|July 20, 2022
N-Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative SymptomsErica Neill, Susan L Rossell, Caitlin Yolland, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|October 22, 2025
A multisite study of the overlap between symptoms and cognition in schizophrenia: Une étude multicentrique sur le chevauchement entre les symptômes et les troubles cognitifs chez les personnes atteintes de schizophrénieRafal M Skiba, Abhijit M Chinchani, Mahesh Menon, et al.
Schizophrenia Research|June 26, 2024
Overlap between individual differences in cognition and symptoms of schizophreniaRafal M Skiba, Abhijit M Chinchani, Mahesh Menon, et al.
Pageof 27

Showing results (241-250 of 263) with videos related to

Sort By:
Pageof 27
The Australian and New Zealand Journal of Psychiatry|December 13, 2019
Meta-analysis of randomised controlled trials with <i>N</i>-acetylcysteine in the treatment of schizophreniaCaitlin Ob Yolland, Donal Hanratty, Erica Neill, et al.
BMC Psychiatry|September 16, 2016
N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptomsSusan L Rossell, Paul S Francis, Cherrie Galletly, et al.
JAMA Network Open|July 28, 2022
Association of Long-Acting Injectable Antipsychotics and Oral Antipsychotics With Disease Relapse, Health Care Use, and Adverse Events Among People With SchizophreniaYue Wei, Vincent K C Yan, Wei Kang, et al.
The Australian and New Zealand Journal of Psychiatry|May 15, 2020
Effectiveness of embedding a specialist preventive care clinician in a community mental health service in increasing preventive care provision: A randomised controlled trialCaitlin Mc Fehily, Kate M Bartlem, John H Wiggers, et al.
Trials|September 11, 2016
The Stroke and Carer Optimal Health Program (SCOHP) to enhance psychosocial health: study protocol for a randomized controlled trialCatherine Brasier, Chantal F Ski, David R Thompson, et al.
The Lancet Regional Health. Western Pacific|June 23, 2025
A decade of Benzodiazepine and Z-drug use in Hong Kong: a longitudinal studyKyung Jin Lee, Yue Wei, Shek-Ming Leung, et al.
Nutritional Neuroscience|May 31, 2018
Improvement of cognitive function in schizophrenia with <i>N</i>-acetylcysteine: A theoretical reviewCaitlin O B Yolland, Andrea Phillipou, David J Castle, et al.
Schizophrenia Bulletin|July 20, 2022
N-Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative SymptomsErica Neill, Susan L Rossell, Caitlin Yolland, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|October 22, 2025
A multisite study of the overlap between symptoms and cognition in schizophrenia: Une étude multicentrique sur le chevauchement entre les symptômes et les troubles cognitifs chez les personnes atteintes de schizophrénieRafal M Skiba, Abhijit M Chinchani, Mahesh Menon, et al.
Schizophrenia Research|June 26, 2024
Overlap between individual differences in cognition and symptoms of schizophreniaRafal M Skiba, Abhijit M Chinchani, Mahesh Menon, et al.
Pageof 27